American Association for Cancer Research
00085472can124028-sup-methfiglegtab1-3.pdf (125.46 kB)

Supplementary Methods, Figure Legends, Tables 1 - 3 from Nkx2-8 Downregulation Promotes Angiogenesis and Activates NF-κB in Esophageal Cancer

Download (125.46 kB)
journal contribution
posted on 2023-03-30, 21:47 authored by Chuyong Lin, Libing Song, Hui Gong, Aibin Liu, Xi Lin, Jueheng Wu, Mengfeng Li, Jun Li

PDF file - 125K, Supplementary Table 1. Clinicopathological characteristics of studied patients and expression of Nkx2-8 in ESCC; Supplementary Table 2. Correlation between the clinicopathological features and expression of Nkx2-8; Supplementary Table 3. Univariate and multivariate analysis of different prognostic parameters in patients with ESCC by Cox-regression analysis.



Angiogenesis is a major clinical feature of esophageal squamous cell carcinoma (ESCC), an aggressive disease of increasing incidence in developed countries. In ESCCs, the proangiogenic factor VEGF-C is an independent prognostic factor for ESCC, where understanding the mechanisms of VEGF-C upregulation may cue possible therapeutic insights. Here, we report that expression of the transcription factor Nkx2-8 is downregulated in ESCCs where it inversely correlates with progression and VEGF-C upregulation. Patients with ESCCs with lower Nkx2-8 expression exhibited reduced overall survival. Modulating expression of Nkx2-8 up or down inhibited or enhanced, respectively, proangiogenic activity in vitro and in vivo. Mechanistic investigations showed that Nkx2-8 repressed NF-κB activity by restraining nuclear localization of NF-κB p65 via downregulation of AKIP1, a NF-κB p65 binding partner, and also by directly targeting the AKIP1 promoter. We confirmed evidence for the importance of the Nkx2-8/AKIP1/NF-κB axis identified in ESCC cell models through an immunohistochemical analysis of a large cohort of human ESCC specimens. Taken together, our results showed that Nkx2-8 functions as a tumor suppressor in ESCCs, the downregulation of which contributes to NF-κB activation and ESCC angiogenesis. Cancer Res; 73(12); 3638–48. ©2013 AACR.